China Resources Double-Crane Pharmaceutical (600062.SH) Subsidiary Receives Drug Registration Certificate for Bosentan Dispersible Tablets

Stock News09-29

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH) announced that its wholly-owned subsidiary, Huarun Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. ("Shuanghe Limin"), has recently received the Drug Registration Certificate for Bosentan Dispersible Tablets from the National Medical Products Administration (NMPA).

The approved indication for Bosentan Dispersible Tablets is for Pulmonary Arterial Hypertension (PAH) (WHO Group 1): to improve pulmonary vascular resistance (PVR) in pediatric patients aged ≥3 years with idiopathic or congenital PAH; and for the treatment of adult patients with Pulmonary Arterial Hypertension (PAH) (WHO Group 1) in WHO Functional Class II-IV.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123961361?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 17:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123961361","market":"fut","top_or_hot":-1,"title":"China Resources Double-Crane Pharmaceutical (600062.SH) Subsidiary Receives Drug Registration Certificate for Bosentan Dispersible Tablets","media":"Stock News","content":"<p>China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH) announced that its wholly-owned subsidiary, Huarun Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. (\"Shuanghe Limin\"), has recently received the Drug Registration Certificate for Bosentan Dispersible Tablets from the National Medical Products Administration (NMPA).</p>\n<p>The approved indication for Bosentan Dispersible Tablets is for Pulmonary Arterial Hypertension (PAH) (WHO Group 1): to improve pulmonary vascular resistance (PVR) in pediatric patients aged ≥3 years with idiopathic or congenital PAH; and for the treatment of adult patients with Pulmonary Arterial Hypertension (PAH) (WHO Group 1) in WHO Functional Class II-IV.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Double-Crane Pharmaceutical (600062.SH) Subsidiary Receives Drug Registration Certificate for Bosentan Dispersible Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Double-Crane Pharmaceutical (600062.SH) Subsidiary Receives Drug Registration Certificate for Bosentan Dispersible Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-29 17:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH) announced that its wholly-owned subsidiary, Huarun Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. (\"Shuanghe Limin\"), has recently received the Drug Registration Certificate for Bosentan Dispersible Tablets from the National Medical Products Administration (NMPA).</p>\n<p>The approved indication for Bosentan Dispersible Tablets is for Pulmonary Arterial Hypertension (PAH) (WHO Group 1): to improve pulmonary vascular resistance (PVR) in pediatric patients aged ≥3 years with idiopathic or congenital PAH; and for the treatment of adult patients with Pulmonary Arterial Hypertension (PAH) (WHO Group 1) in WHO Functional Class II-IV.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1123961361","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123961361","pubTimestamp":1759139914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH) announced that its wholly-owned subsidiary, Huarun Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. (\"Shuanghe Limin\"), has recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0239":"医药制造","BK0028":"国家队","BK0185":"二线龙头","BK0188":"融资融券","BK0175":"白马股","BK0010":"央企"},"translate_title":"华润双鹤药业（600062.SH）子公司获波生坦分散片药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1},"content_text":"China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH) announced that its wholly-owned subsidiary, Huarun Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. (\"Shuanghe Limin\"), has recently received the Drug Registration Certificate for Bosentan Dispersible Tablets from the National Medical Products Administration (NMPA).\nThe approved indication for Bosentan Dispersible Tablets is for Pulmonary Arterial Hypertension (PAH) (WHO Group 1): to improve pulmonary vascular resistance (PVR) in pediatric patients aged ≥3 years with idiopathic or congenital PAH; and for the treatment of adult patients with Pulmonary Arterial Hypertension (PAH) (WHO Group 1) in WHO Functional Class II-IV.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123961361","isCrawlerRequest":true}